Prokidney Corp (PROK)

$1.51

+0.01

(+0.67%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Prokidney Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.4% return, outperforming this stock by 161.3%

Performance

  • $1.50
    $1.55
    $1.51
    downward going graph

    0.66%

    Downside

    Day's Volatility :3.22%

    Upside

    2.57%

    downward going graph
  • $1.12
    $14.19
    $1.51
    downward going graph

    25.83%

    Downside

    52 Weeks Volatility :92.11%

    Upside

    89.36%

    downward going graph

Returns

PeriodProkidney CorpIndex (Russel 2000)
3 Months
-12.21%
0.0%
6 Months
-83.05%
0.0%
1 Year
-86.87%
-6.4%
3 Years
-84.85%
-22.6%

Highlights

Market Capitalization
1.8B
Book Value
- $17.74
Earnings Per Share (EPS)
-0.58
Wall Street Target Price
9.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-20.01%
Return On Equity TTM
-29.15%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-154.0M
Diluted Eps TTM
-0.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.65
EPS Estimate Next Year
-0.75
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Prokidney Corp(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 517.88%

Current $1.51
Target $9.33

Technicals Summary

Sell

Neutral

Buy

Prokidney Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prokidney Corp
Prokidney Corp
-6.79%
-83.05%
-86.87%
-84.85%
-84.85%
Moderna, Inc.
Moderna, Inc.
-4.6%
-14.37%
-30.73%
-33.38%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.48%
18.04%
29.62%
113.96%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
17.34%
33.21%
74.36%
242.01%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.6%
24.03%
49.67%
98.17%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prokidney Corp
Prokidney Corp
NA
NA
NA
-0.65
-0.29
-0.2
NA
-17.74
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prokidney Corp
Prokidney Corp
Buy
$1.8B
-84.85%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • Social Capital Group LLC

    17.05%
  • Morgan Stanley - Brokerage Accounts

    15.15%
  • Suvretta Capital Management, LLC

    5.70%
  • Vanguard Group Inc

    4.85%
  • BlackRock Inc

    4.14%
  • Bleichroeder LP

    2.95%

Company Information

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.

Organization
Prokidney Corp
Employees
87
CEO
Mr. Todd C. Girolamo Esq., J.D., M.B.A.
Industry
Healthcare

FAQs